The current regulatory landscape for the development of peptide drugs may lead companies to perform a variety of small molecule-focussed ADME studies in support of filing packages. The aim of this workshop is for member company scientists to discuss and exchange ideas of peptide ADME related challenges (active participation is expected). Asking the question, if the current activities are suitable for these modalities, and should science-driven decisions on development of such molecules be implemented more in the industry.
If you work in the drug development of peptides, and have such questions (or additional ones), please join in on the debate with us in Gothenburg on 7 September 2020, for a ½ day meeting, prior to the DMDG Open Meeting (8 - 10 September).
To give a flavour for what this meeting is about, the meeting report from the 1st workshop was recently published (and can be found here).
If you have a hot topic you would like to be discussed (or a case story to share) then please contact email@example.com. Join the peptide discussion!!!